Navigation Links
ExonHit Appoints a New Management Board
Date:3/31/2008

ng industry. ExonHit Therapeutics has it all. We all are very excited about working together to exploit these assets. This is the legacy the founders left us and it is our duty to convert them into successful products for the benefit of the patients and of our shareholders. ExonHit Therapeutics has continued to make strong progress since the beginning of 2008 with the registered positive effect of our lead compound (EHT0202) in the clinical Phase 1 "scopolamine" trial and recruitments of patients both in our diagnostics and therapeutics studies going according to plan. I am convinced ExonHit Therapeutics has all the assets and talents to bring to the market innovation patients need."

About ExonHit Therapeutics

http://www.exonhit.com

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer's disease or atherosclerosis.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-cli
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ExonHit Therapeutics - 2007 Financial Results
2. ExonHit Builds A New Organisation
3. ExonHit and bioMerieux Amend Their Strategic Partnership
4. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
5. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
6. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
7. Pharmasset Appoints Herbert J. Conrad as a Director
8. MacroChem Appoints David P. Luci as New CFO
9. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
10. RainDance Appoints Becker Chief Commercial Officer
11. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... BURLINGTON, Mass. , July 1, 2015 /PRNewswire/ ... three most frequently cited advantages of Otezla are ... favorable safety profile, as reported by surveyed rheumatologists. ... and launched for the treatment of active psoriatic ... . The current standard of care includes conventional ...
(Date:7/1/2015)... and BANGALORE, India , July 1, ... company that uses next generation sequencing technology to empower ... A. Storrer as chief executive officer. In his ... be responsible for all strategy, business expansion and worldwide ... has served as Strand,s chairman and CEO since its ...
(Date:7/1/2015)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced that the company will host ... p.m. EDT following its presentation of RVT-101 clinical ... (AAIC). The event will include ... Lawrence Friedhoff , Chief Development Officer, will present ...
(Date:7/1/2015)... ... , ... A newly launched business plan contest will ask startup companies from ... life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small and ... of expert mentorship from a senior industry figure drawn from the Pistoia Alliance membership. ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... movie about giant robots that undergo structural ... a scientific study about structural transformations within single ... of novel materials that will serve next-generation energy ... at the U.S. Department of Energy (DOE),s Lawrence ...
... 8, 2011 Northwest Biotherapeutics (OTC Bulletin Board: ... equity investment on June 28, 2011, by The Richard ... newly issued common stock of the Company to the ... 31, 2011, by investment funds managed by Whitebox Advisors, ...
... 7, 2011 For the first time since stem ... isolated a human blood stem cell in its purest ... regenerating the entire blood system. This breakthrough opens the ... to treat cancer and other debilitating diseases more effectively. ...
Cached Biology Technology:Nanocrystal transformers 2Nanocrystal transformers 3Nanocrystal transformers 4Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe 2Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe 3Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe 4"Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use 2"Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use 3
(Date:6/15/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces that its leading payment security technology, the ... Experience! @ NYC June 18th. Digital Experience! @ ... in technology to over 300 of the top media covering ... Pavilion in New York City from ...
(Date:6/10/2015)... June 10, 2015 According ... Market by Technology (Ultrasound, TOF, Structured Light, Stereo ... Entertainment, Automotive) and by Geography - Trends & ... the market is expected to reach $3,319.71 Million ... between 2015 and 2020. Browse 71 ...
(Date:6/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ), a ... featuring its Precision Cancer Monitoring SM platform will be ... conference in San Diego, CA on ... Series: Integrating Clinical Genomics and Cancer Therapy in ... "We continue to advance our clinical programs ...
Breaking Biology News(10 mins):Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 33D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4
... recycling processes may generate more greenhouse gases than traditional ... to continue keep wastewater recycling among the water-resource tools ... a new paper by Amy Townsend-Small, assistant professor of ... a team of researchers from the University of California, ...
... found that individuals who carry a mutation in a gene ... of cancer mesothelioma, and melanoma of the eye. ... mineral fibers, their risk of developing mesothelioma, an aggressive cancer ... markedly increased. The study, published online Aug. 28, ...
... August 29, 2011, Shenzhen, China The Institute of ... Crops Research Institute of the Chinese Academy of Agricultural ... today that they were among the research organizations comprising ... (BrGSPC) that completed the genome sequence and analysis of ...
Cached Biology News:Wastewater recycling can multiply greenhouse gas emissions 2Wastewater recycling can multiply greenhouse gas emissions 3NIH-funded researchers discover genetic link to mesothelioma 2NIH-funded researchers discover genetic link to mesothelioma 3The genome of mesopolyploid crop Brassica rapa sheds new light on the study of genome evolution 2The genome of mesopolyploid crop Brassica rapa sheds new light on the study of genome evolution 3
... is the most thoroughly characterized enzyme available ... its overall utility and efficacy. , Its ... PCR applications. , It is QC ... AmpliTaq DNA Polymerase is a 94 kDa ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... DNA Polymerase is a versatile and easy-to ... PCR applications. GCpro Taq DNA Polymerase is ... E. coli, containing the DNA polymerase I ... a highly processive 5'-3' DNA polymerase activity. ...
Aspergillus (IgG) Ab EIA Sample Size: 100 l...
Biology Products: